Triflusal

Triflusal is an antiplatelet agent structurally related to the salicylate group of compounds, but it is not derived from aspirin (acetylsalicylic acid). Platelet antiaggregant properties of triflusal and its active 3-hydroxy-4-trifluoro-methylbenzoic acid metabolite are primarily mediated by specifi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drugs (New York, N.Y.) N.Y.), 1998-06, Vol.55 (6), p.823-835
Hauptverfasser: MCNEELY, W, GOA, K. L
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 835
container_issue 6
container_start_page 823
container_title Drugs (New York, N.Y.)
container_volume 55
creator MCNEELY, W
GOA, K. L
description Triflusal is an antiplatelet agent structurally related to the salicylate group of compounds, but it is not derived from aspirin (acetylsalicylic acid). Platelet antiaggregant properties of triflusal and its active 3-hydroxy-4-trifluoro-methylbenzoic acid metabolite are primarily mediated by specific inhibition of platelet arachidonic acid metabolism. Triflusal, compared with placebo for 6 months, significantly reduced the incidence of nonfatal myocardial infarction in patients with unstable angina. In patients with peripheral arteriopathy, total and pain free walking distances were markedly improved in triflusal compared with placebo recipients. The cumulative event rate for stroke, ischemic cardiopathy and vascular death was lower, but not significantly different, in patients with atherothrombotic stroke who received triflusal than in aspirin recipients. Differences were significant, and favoured triflusal, in a subgroup of patients with > 70% carotid stenosis. Prophylaxis with triflusal for 6 months after aortocoronary vein grafting reduced the number of new distal anastomosis occlusions and the graft attrition rate more than aspirin or placebo. The incidence of deep vein thrombosis or pulmonary embolism in more than 500 patients undergoing hip surgery was similar for these 3 treatments. The amount of blood transfused was significantly reduced in triflusal compared with aspirin recipients who underwent hip surgery. Risk of haemorrhage was also reduced in ischemic stroke patients receiving triflusal versus aspirin.
doi_str_mv 10.2165/00003495-199855060-00011
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79925426</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79925426</sourcerecordid><originalsourceid>FETCH-LOGICAL-c339t-a1d0b284f07de7f86c9fdc949682726c1041dff1a26145957ce0f1516f9e91f03</originalsourceid><addsrcrecordid>eNo9UE1LAzEQDaLUtfoTBA_iLZrJ5mPnKMWqUPBSzyHNJrCSbWvSPfjvTe26cxnmvTdvmEfIHbBHDko-sVK1QEkBsZGSKUYLAnBGKgCNBZbsnFQF4lQppS_JVc5fxxElzsgMFWiJuiLVOnUhDtnGa3IRbMz-Zuxz8rl8WS_e6Orj9X3xvKKurvFALbRswxsRmG69Do1yGFqHAlXDNVcOmIA2BLBcgZAotfMsgAQV0CMEVs_Jw8l3n3bfg88H03fZ-Rjt1u-GbDQil4KrImxOQpd2OScfzD51vU0_Bpg5pmD-UzBTCuYvhbJ6O94YNr1vp8Xx7cLfj7zNzsaQ7NZ1eZLxmjVYrH8B-AthYQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79925426</pqid></control><display><type>article</type><title>Triflusal</title><source>MEDLINE</source><source>SpringerLink (Online service)</source><creator>MCNEELY, W ; GOA, K. L</creator><creatorcontrib>MCNEELY, W ; GOA, K. L</creatorcontrib><description>Triflusal is an antiplatelet agent structurally related to the salicylate group of compounds, but it is not derived from aspirin (acetylsalicylic acid). Platelet antiaggregant properties of triflusal and its active 3-hydroxy-4-trifluoro-methylbenzoic acid metabolite are primarily mediated by specific inhibition of platelet arachidonic acid metabolism. Triflusal, compared with placebo for 6 months, significantly reduced the incidence of nonfatal myocardial infarction in patients with unstable angina. In patients with peripheral arteriopathy, total and pain free walking distances were markedly improved in triflusal compared with placebo recipients. The cumulative event rate for stroke, ischemic cardiopathy and vascular death was lower, but not significantly different, in patients with atherothrombotic stroke who received triflusal than in aspirin recipients. Differences were significant, and favoured triflusal, in a subgroup of patients with &gt; 70% carotid stenosis. Prophylaxis with triflusal for 6 months after aortocoronary vein grafting reduced the number of new distal anastomosis occlusions and the graft attrition rate more than aspirin or placebo. The incidence of deep vein thrombosis or pulmonary embolism in more than 500 patients undergoing hip surgery was similar for these 3 treatments. The amount of blood transfused was significantly reduced in triflusal compared with aspirin recipients who underwent hip surgery. Risk of haemorrhage was also reduced in ischemic stroke patients receiving triflusal versus aspirin.</description><identifier>ISSN: 0012-6667</identifier><identifier>EISSN: 1179-1950</identifier><identifier>DOI: 10.2165/00003495-199855060-00011</identifier><identifier>PMID: 9617597</identifier><identifier>CODEN: DRUGAY</identifier><language>eng</language><publisher>Auckland: Adis International</publisher><subject><![CDATA[Adult ; Angina Pectoris - complications ; Angina Pectoris - drug therapy ; Animals ; Aspirin - therapeutic use ; Biological and medical sciences ; Blood. Blood coagulation. Reticuloendothelial system ; Carotid Stenosis - drug therapy ; Humans ; In Vitro Techniques ; Medical sciences ; Middle Aged ; Myocardial Infarction - prevention & control ; Pharmacology. Drug treatments ; Platelet Aggregation Inhibitors - administration & dosage ; Platelet Aggregation Inhibitors - pharmacokinetics ; Platelet Aggregation Inhibitors - therapeutic use ; Postoperative Complications - prevention & control ; Pulmonary Embolism - prevention & control ; Randomized Controlled Trials as Topic ; Salicylates - administration & dosage ; Salicylates - pharmacokinetics ; Salicylates - therapeutic use ; Thrombophlebitis - prevention & control]]></subject><ispartof>Drugs (New York, N.Y.), 1998-06, Vol.55 (6), p.823-835</ispartof><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c339t-a1d0b284f07de7f86c9fdc949682726c1041dff1a26145957ce0f1516f9e91f03</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2308900$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9617597$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MCNEELY, W</creatorcontrib><creatorcontrib>GOA, K. L</creatorcontrib><title>Triflusal</title><title>Drugs (New York, N.Y.)</title><addtitle>Drugs</addtitle><description>Triflusal is an antiplatelet agent structurally related to the salicylate group of compounds, but it is not derived from aspirin (acetylsalicylic acid). Platelet antiaggregant properties of triflusal and its active 3-hydroxy-4-trifluoro-methylbenzoic acid metabolite are primarily mediated by specific inhibition of platelet arachidonic acid metabolism. Triflusal, compared with placebo for 6 months, significantly reduced the incidence of nonfatal myocardial infarction in patients with unstable angina. In patients with peripheral arteriopathy, total and pain free walking distances were markedly improved in triflusal compared with placebo recipients. The cumulative event rate for stroke, ischemic cardiopathy and vascular death was lower, but not significantly different, in patients with atherothrombotic stroke who received triflusal than in aspirin recipients. Differences were significant, and favoured triflusal, in a subgroup of patients with &gt; 70% carotid stenosis. Prophylaxis with triflusal for 6 months after aortocoronary vein grafting reduced the number of new distal anastomosis occlusions and the graft attrition rate more than aspirin or placebo. The incidence of deep vein thrombosis or pulmonary embolism in more than 500 patients undergoing hip surgery was similar for these 3 treatments. The amount of blood transfused was significantly reduced in triflusal compared with aspirin recipients who underwent hip surgery. Risk of haemorrhage was also reduced in ischemic stroke patients receiving triflusal versus aspirin.</description><subject>Adult</subject><subject>Angina Pectoris - complications</subject><subject>Angina Pectoris - drug therapy</subject><subject>Animals</subject><subject>Aspirin - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Blood. Blood coagulation. Reticuloendothelial system</subject><subject>Carotid Stenosis - drug therapy</subject><subject>Humans</subject><subject>In Vitro Techniques</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Myocardial Infarction - prevention &amp; control</subject><subject>Pharmacology. Drug treatments</subject><subject>Platelet Aggregation Inhibitors - administration &amp; dosage</subject><subject>Platelet Aggregation Inhibitors - pharmacokinetics</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Postoperative Complications - prevention &amp; control</subject><subject>Pulmonary Embolism - prevention &amp; control</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Salicylates - administration &amp; dosage</subject><subject>Salicylates - pharmacokinetics</subject><subject>Salicylates - therapeutic use</subject><subject>Thrombophlebitis - prevention &amp; control</subject><issn>0012-6667</issn><issn>1179-1950</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9UE1LAzEQDaLUtfoTBA_iLZrJ5mPnKMWqUPBSzyHNJrCSbWvSPfjvTe26cxnmvTdvmEfIHbBHDko-sVK1QEkBsZGSKUYLAnBGKgCNBZbsnFQF4lQppS_JVc5fxxElzsgMFWiJuiLVOnUhDtnGa3IRbMz-Zuxz8rl8WS_e6Orj9X3xvKKurvFALbRswxsRmG69Do1yGFqHAlXDNVcOmIA2BLBcgZAotfMsgAQV0CMEVs_Jw8l3n3bfg88H03fZ-Rjt1u-GbDQil4KrImxOQpd2OScfzD51vU0_Bpg5pmD-UzBTCuYvhbJ6O94YNr1vp8Xx7cLfj7zNzsaQ7NZ1eZLxmjVYrH8B-AthYQ</recordid><startdate>19980601</startdate><enddate>19980601</enddate><creator>MCNEELY, W</creator><creator>GOA, K. L</creator><general>Adis International</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19980601</creationdate><title>Triflusal</title><author>MCNEELY, W ; GOA, K. L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c339t-a1d0b284f07de7f86c9fdc949682726c1041dff1a26145957ce0f1516f9e91f03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adult</topic><topic>Angina Pectoris - complications</topic><topic>Angina Pectoris - drug therapy</topic><topic>Animals</topic><topic>Aspirin - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Blood. Blood coagulation. Reticuloendothelial system</topic><topic>Carotid Stenosis - drug therapy</topic><topic>Humans</topic><topic>In Vitro Techniques</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Myocardial Infarction - prevention &amp; control</topic><topic>Pharmacology. Drug treatments</topic><topic>Platelet Aggregation Inhibitors - administration &amp; dosage</topic><topic>Platelet Aggregation Inhibitors - pharmacokinetics</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Postoperative Complications - prevention &amp; control</topic><topic>Pulmonary Embolism - prevention &amp; control</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Salicylates - administration &amp; dosage</topic><topic>Salicylates - pharmacokinetics</topic><topic>Salicylates - therapeutic use</topic><topic>Thrombophlebitis - prevention &amp; control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MCNEELY, W</creatorcontrib><creatorcontrib>GOA, K. L</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Drugs (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MCNEELY, W</au><au>GOA, K. L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Triflusal</atitle><jtitle>Drugs (New York, N.Y.)</jtitle><addtitle>Drugs</addtitle><date>1998-06-01</date><risdate>1998</risdate><volume>55</volume><issue>6</issue><spage>823</spage><epage>835</epage><pages>823-835</pages><issn>0012-6667</issn><eissn>1179-1950</eissn><coden>DRUGAY</coden><abstract>Triflusal is an antiplatelet agent structurally related to the salicylate group of compounds, but it is not derived from aspirin (acetylsalicylic acid). Platelet antiaggregant properties of triflusal and its active 3-hydroxy-4-trifluoro-methylbenzoic acid metabolite are primarily mediated by specific inhibition of platelet arachidonic acid metabolism. Triflusal, compared with placebo for 6 months, significantly reduced the incidence of nonfatal myocardial infarction in patients with unstable angina. In patients with peripheral arteriopathy, total and pain free walking distances were markedly improved in triflusal compared with placebo recipients. The cumulative event rate for stroke, ischemic cardiopathy and vascular death was lower, but not significantly different, in patients with atherothrombotic stroke who received triflusal than in aspirin recipients. Differences were significant, and favoured triflusal, in a subgroup of patients with &gt; 70% carotid stenosis. Prophylaxis with triflusal for 6 months after aortocoronary vein grafting reduced the number of new distal anastomosis occlusions and the graft attrition rate more than aspirin or placebo. The incidence of deep vein thrombosis or pulmonary embolism in more than 500 patients undergoing hip surgery was similar for these 3 treatments. The amount of blood transfused was significantly reduced in triflusal compared with aspirin recipients who underwent hip surgery. Risk of haemorrhage was also reduced in ischemic stroke patients receiving triflusal versus aspirin.</abstract><cop>Auckland</cop><pub>Adis International</pub><pmid>9617597</pmid><doi>10.2165/00003495-199855060-00011</doi><tpages>13</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0012-6667
ispartof Drugs (New York, N.Y.), 1998-06, Vol.55 (6), p.823-835
issn 0012-6667
1179-1950
language eng
recordid cdi_proquest_miscellaneous_79925426
source MEDLINE; SpringerLink (Online service)
subjects Adult
Angina Pectoris - complications
Angina Pectoris - drug therapy
Animals
Aspirin - therapeutic use
Biological and medical sciences
Blood. Blood coagulation. Reticuloendothelial system
Carotid Stenosis - drug therapy
Humans
In Vitro Techniques
Medical sciences
Middle Aged
Myocardial Infarction - prevention & control
Pharmacology. Drug treatments
Platelet Aggregation Inhibitors - administration & dosage
Platelet Aggregation Inhibitors - pharmacokinetics
Platelet Aggregation Inhibitors - therapeutic use
Postoperative Complications - prevention & control
Pulmonary Embolism - prevention & control
Randomized Controlled Trials as Topic
Salicylates - administration & dosage
Salicylates - pharmacokinetics
Salicylates - therapeutic use
Thrombophlebitis - prevention & control
title Triflusal
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T10%3A28%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Triflusal&rft.jtitle=Drugs%20(New%20York,%20N.Y.)&rft.au=MCNEELY,%20W&rft.date=1998-06-01&rft.volume=55&rft.issue=6&rft.spage=823&rft.epage=835&rft.pages=823-835&rft.issn=0012-6667&rft.eissn=1179-1950&rft.coden=DRUGAY&rft_id=info:doi/10.2165/00003495-199855060-00011&rft_dat=%3Cproquest_cross%3E79925426%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79925426&rft_id=info:pmid/9617597&rfr_iscdi=true